Rapport Therapeutics (RAPP) Reiterated at Market Outperform by Citizens on Positive Ph2 Results

Wed, 23 Sep 2026 04:48:12 -0400

Citizens analyst Jason Butler reiterated a Market Outperform rating and $80.00 price target on Rapport Therapeutics (NASDAQ: RAPP).

The analyst commented, "We are encouraged by the KOLs’ support for the potential of positive results in the Phase 2 trial, and we believe RAP-219 could offer a novel approach to treating patients with bipolar mania, differentiated through its established mechanism and tolerability profile. In our view, the long-acting injectable RAP-219 formulation could be transformative for bipolar mania patients in improving adherence."

For an analyst ratings summary and ratings history on Rapport Therapeutics click here. For more ratings news on Rapport Therapeutics

Raymond James Reiterates Strong Buy Rating on Rapport Therapeutics (RAPP)

Tue, 22 Sep 2026 16:05:46 -0400

Raymond James analyst Tiago Fauth reiterated a Strong Buy rating and $75.00 price target on Rapport Therapeutics (NASDAQ: RAPP).

The analyst comments "Thoughts on the stock. Today’s KOL discussion reinforced the framework we had laid out in our bipolar mania deep dive (link): there’s a real unmet need in bipolar mania, and penetration for a novel MoA with RAP-219’s expected tolerability profile could be substantial. We continue to believe RAP-219’s bipolar mania readout is one of the most asymmetric catalysts in SMID biotech, as XENE ($39.06/Not Covered) sets a highly relevant precedent and offers insights into how RAPP could trade following

Rapport Therapeutics (RAPP) Reiterated at Buy by Stifel

Wed, 16 Sep 2026 09:35:28 -0400

(Updated - September 16, 2026 9:35 AM EDT)

Stifel analyst Paul Matteis reiterated a Buy rating and $56.00 price target on Rapport Therapeutics (NASDAQ: RAPP).

The analyst commented, "We're reiterating our Buy rating on RAPP, where our thesis is driven by (1) our bullish view on RAP-219 in epilepsy, where we think the drug is mostly derisked and (2) our cautious optimism around upcoming bipolar mania data, which we view as a high risk/high reward readout. Within this note we lay out the 5 key questions ahead of the data, which center around the mechanistic rationale, "bar" for success, considerations around safety,

Rapport Therapeutics (RAPP) PT Raised to $75 at BTIG

Wed, 16 Sep 2026 06:06:14 -0400

BTIG analyst Kambiz Yazdi raised the price target on Rapport Therapeutics (NASDAQ: RAPP) to $75.00 (from $65.00) while maintaining a Buy rating.

The analyst comments "We are increasing our price target to $75 and raising our probability of success for RAP-219 in bipolar mania to 45% (from 35%). Our increased PoS reflects our higher conviction that RAP-219's TARPγ8-selective mechanism is well-matched to the neurobiology of acute mania, Rapport's strong clinical execution, and the favorable risk/reward setup heading into the October readout."

Rapport Therapeutics (RAPP) PT Raised to $75 at BTIG

Wed, 16 Sep 2026 06:06:14 -0400

BTIG analyst Kambiz Yazdi raised the price target on Rapport Therapeutics (NASDAQ: RAPP) to $75.00 (from $65.00) while maintaining a Buy rating.

Truist on Rapport Therapeutics (RAPP): 'Assessing the RAP-219 Bipolar Mania Opportunity Ahead of October PoC Data'

Tue, 15 Sep 2026 11:13:17 -0400

Truist Securities analyst Danielle Brill reiterated a Buy rating and $56.00 price target on Rapport Therapeutics (NASDAQ: RAPP).

The analyst commented: "Assessing the RAP-219 Bipolar Mania Opportunity Ahead of October PoC Data; We view the bipolar mania study as an exploratory PoC trial given the limited evidence supporting both (1) the underlying mechanism in acute mania and (2) the selected dose regimen in this setting. While RAP-219 may ultimately be better positioned as a chronic mood-stabilizing therapy for bipolar disorder, positive data from this study are likely necessary to unlock meaningful value in the indication. Although we have limited conviction in

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events:

Cantor Global Healthcare Conference (New York City) – fireside chat on Wednesday, September 9, 2026, at 1:35-2:05 pm ET.

TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit (virtual) – fireside chat on Wednesday, September 23, 2026, at 1:30-1:55 pm ET.

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

Cantor Global Healthcare Conference (New York City) – fireside chat on Wednesday, September 9, 2026, at 1:35-2:05 pm ET.

TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit (virtual) – fireside chat on Wednesday, September 23, 2026, at 1:30-1:55 pm ET.

Form 4 Rapport Therapeutics, For: Aug 25 Filed by: Ceesay Abraham

Wed, 26 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260826/26981550.html

Form 4 Rapport Therapeutics, For: Aug 25 Filed by: Ceesay Abraham

Wed, 26 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260826/26981550.html

Form 4 Rapport Therapeutics, For: Aug 24 Filed by: Yeleswaram Krishnaswamy

Wed, 26 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260826/26981380.html

Form 4 Rapport Therapeutics, For: Aug 24 Filed by: Yeleswaram Krishnaswamy

Wed, 26 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260826/26981380.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Tue, 25 Aug 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260825/26975110.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Tue, 25 Aug 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260825/26975110.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Mon, 24 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260824/26968448.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Mon, 24 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260824/26968448.html

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Mon, 24 Aug 2026 07:00:00 -0400

BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 22, 2026, at 12:30 PM ET. To register for the event, please click here.

The event will feature leading experts in bipolar disorder Mauricio Tohen, MD, DrPH, MBA (University of New Mexico Health Science Center), and Gary Sachs,

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Mon, 24 Aug 2026 07:00:00 -0400

BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 22, 2026, at 12:30 PM ET. To register for the event, please click here.

The event will feature leading experts in bipolar disorder Mauricio Tohen, MD, DrPH, MBA (University of New Mexico Health Science Center), and Gary Sachs,

Form 4 Rapport Therapeutics, For: Aug 19 Filed by: Yeleswaram Krishnaswamy

Thu, 20 Aug 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260820/26956240.html

Form 4 Rapport Therapeutics, For: Aug 19 Filed by: Yeleswaram Krishnaswamy

Thu, 20 Aug 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260820/26956240.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Wed, 19 Aug 2026 16:38:00 -0400
si-local-file:///var/storage/secattach/20260819/26950627.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Wed, 19 Aug 2026 16:38:00 -0400
si-local-file:///var/storage/secattach/20260819/26950627.html

Rapport Therapeutics (RAPP) PT Raised to $75 at Raymond James

Mon, 17 Aug 2026 06:16:19 -0400

Raymond James analyst Tiago Fauth raised the price target on Rapport Therapeutics (NASDAQ: RAPP) to $75.00 (from $68.00) while maintaining a Strong Buy rating.
The analyst comments "We believe RAP-219’s bipolar mania readout is one of the most asymmetric catalysts in SMID biotech. RAPP is up 56% YTD (vs. XBI up 29%), but we believe this move had little to do with the bipolar program, as the move from ~$1B to ~$2B EV is the exact same pattern we saw with XENE following their Ph2 FOS data. We think XENE ($62.35/Not Covered) sets a highly relevant precedent and offers insights into

Rapport Therapeutics (RAPP) PT Raised to $75 at Raymond James

Mon, 17 Aug 2026 06:16:19 -0400

Raymond James analyst Tiago Fauth raised the price target on Rapport Therapeutics (NASDAQ: RAPP) to $75.00 (from $68.00) while maintaining a Strong Buy rating.
The analyst comments "We believe RAP-219’s bipolar mania readout is one of the most asymmetric catalysts in SMID biotech. RAPP is up 56% YTD (vs. XBI up 29%), but we believe this move had little to do with the bipolar program, as the move from ~$1B to ~$2B EV is the exact same pattern we saw with XENE following their Ph2 FOS data. We think XENE ($62.35/Not Covered) sets a highly relevant precedent and offers insights into

Form SCHEDULE 13G/A Rapport Therapeutics, Filed by: Third Rock Ventures V, L.P.

Fri, 14 Aug 2026 16:20:00 -0400
si-local-file:///var/storage/secattach/20260814/26930848.html

StreetInsider.com News Articles

Rapport Therapeutics (RAPP) Reiterated at Market Outperform by Citizens on Positive Ph2 Results

Raymond James Reiterates Strong Buy Rating on Rapport Therapeutics (RAPP)

Rapport Therapeutics (RAPP) Reiterated at Buy by Stifel

Rapport Therapeutics (RAPP) PT Raised to $75 at BTIG

Rapport Therapeutics (RAPP) PT Raised to $75 at BTIG

Truist on Rapport Therapeutics (RAPP): 'Assessing the RAP-219 Bipolar Mania Opportunity Ahead of October PoC Data'

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Form 4 Rapport Therapeutics, For: Aug 25 Filed by: Ceesay Abraham

Form 4 Rapport Therapeutics, For: Aug 25 Filed by: Ceesay Abraham

Form 4 Rapport Therapeutics, For: Aug 24 Filed by: Yeleswaram Krishnaswamy

Form 4 Rapport Therapeutics, For: Aug 24 Filed by: Yeleswaram Krishnaswamy

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Form 4 Rapport Therapeutics, For: Aug 19 Filed by: Yeleswaram Krishnaswamy

Form 4 Rapport Therapeutics, For: Aug 19 Filed by: Yeleswaram Krishnaswamy

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Rapport Therapeutics (RAPP) PT Raised to $75 at Raymond James

Rapport Therapeutics (RAPP) PT Raised to $75 at Raymond James

Form SCHEDULE 13G/A Rapport Therapeutics, Filed by: Third Rock Ventures V, L.P.